INSP on NYSE
Inspire Medical Systems (United States)
We are a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea ("OSA").4 From its latest annual report
Price unavailable
Last updated Oct 19, 2026.
Overview
2007Founded1
Compare with Orthofix Medical Inc., Tandem Diabetes Care, Inc. or AbioMed, or pick any stock.
- TickerINSP on NYSE1
- IndustrySurgical & Medical Instruments & Apparatus1
- HeadquartersMaple Grove1
- Websitewww.inspiresleep.com
- Incorporated inDE3
- Business address5500 Wayzata Blvd, Suite 1600, Golden Valley, Mn 554163
- Filer categoryLarge accelerated filer3
See how the biggest companies compare on our leaderboards
We are a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea ("OSA"). Our proprietary Inspire system is the first FDA, European Union ("EU") Regulation No. 2017/745 ("MDR" or "EU Medical Devices Regulation"), and Japan Pharmaceuticals and Medical Devices Agency-approved neurostimulation technology of its kind that provides a safe and effective treatment for patients with moderate to severe OSA. We have developed a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. A significant body of clinical data, which includes a publication in the New England Journal of Medicine , multiple publications in leading respiratory, ear, nose and throat ("ENT") and sleep medicine journals, and more…4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
85.4%Gross margin5
5.6%Operating margin5
15.9%Net margin5
13.6%Revenue growth, 20255
18.6%Return on equity5
$78.5MFree cash flow5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Regions
United States brought in 96% of the revenue Inspire Medical Systems (United States) broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $606.2M | $771.0M | $872.1M |
| Outside the United States | $18.6M | $31.8M | $39.9M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue12¢$133.2M
- Research and development9¢$103.2M
- Selling, general and admin58¢$624.6M
- Income tax7¢$79.7M
- Profit13¢$145.4M
Out of $912.0M in revenue.5
Where each dollar of operating cash went, fiscal 2025
- Capital spending18¢$38.5M
- Share buybacks82¢$175.0M
Out of $117.0M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.5
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | $912.0M | $802.8M | $624.8M |
| Cost of goods sold | $133.2M | $123.0M | $96.6M |
| Gross profit | $778.8M | $679.8M | $528.2M |
| Research and development | $103.2M | $114.1M | $116.5M |
| Selling, general and administrative | $624.6M | $529.6M | $452.0M |
| Total operating expenses | $727.8M | $643.7M | $568.5M |
| Operating income (loss) | $51.0M | $36.1M | -$40.3M |
| Interest and dividend income | -$17.5M | -$23.2M | -$20.6M |
| Interest expense | $137.0K | $22.0K | $0 |
| Other expense, net | $2.7M | $855.0K | $195.0K |
| Total other income | -$14.7M | -$22.4M | -$20.4M |
| Income (loss) before income taxes | $65.7M | $58.5M | -$19.9M |
| Income tax (benefit) expense | -$79.7M | $4.9M | $1.2M |
| Net income (loss) | $145.4M | $53.5M | -$21.2M |
| Foreign currency translation (loss) gain | -$296.0K | -$65.0K | $140.0K |
| Unrealized gain (loss) on investments | $224.0K | -$199.0K | $746.0K |
| Total comprehensive income (loss) | $145.3M | $53.2M | -$20.3M |
| Basic (in dollars per share) | $4.95 | $1.80 | -$0.72 |
| Diluted (in dollars per share) | $4.89 | $1.75 | -$0.72 |
| Basic (in shares) | 29.4M shares | 29.8M shares | 29.3M shares |
| Diluted (in shares) | 29.8M shares | 30.5M shares | 29.3M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $104.8M | $150.2M | ||
| Investments, short-term | $203.5M | $295.4M | ||
| Accounts receivable, net of allowance for credit losses of $1,080 and $880, respectively | $119.7M | $93.1M | ||
| Inventories, net | $145.3M | $80.1M | ||
| Prepaid expenses and other current assets | $10.4M | $12.1M | ||
| Total current assets | $583.7M | $630.8M | ||
| Investments, long-term | $96.3M | $71.0M | ||
| Property and equipment, net | $97.9M | $71.9M | ||
| Operating lease right-of-use assets | $23.5M | $23.3M | ||
| Deferred tax assets | $88.7M | $13.0K | ||
| Other non-current assets | $17.3M | $11.3M | ||
| Total assets | $907.3M | $808.4M | ||
| Accounts payable | $36.6M | $38.7M | ||
| Accrued expenses | $59.5M | $49.8M | ||
| Total current liabilities | $96.1M | $88.5M | ||
| Operating lease liabilities, non-current portion | $30.0M | $30.0M | ||
| Other non-current liabilities | $104.0K | $148.0K | ||
| Total liabilities | $126.2M | $118.7M | ||
| Preferred Stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding | $0 | $0 | ||
| Common Stock, $0.001 par value, 200,000,000 shares authorized; 28,579,015 and 29,740,176 shares issued and outstanding at December 31, 2025 and 2024, respectively | $29.0K | $30.0K | ||
| Additional paid-in capital | $927.2M | $981.0M | ||
| Accumulated other comprehensive income | $464.0K | $536.0K | ||
| Accumulated deficit | -$146.5M | -$291.9M | ||
| Total stockholders' equity | $781.2M | $689.7M | $572.5M | $496.0M |
| Total liabilities and stockholders' equity | $907.3M | $808.4M | ||
| Allowance for credit loss | $1.1M | $880.0K | $1.6M | $36.0K |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred stock, issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, authorized (in shares) | 200.0M shares | 200.0M shares | ||
| Common stock, issued (in shares) | 28.6M shares | 29.7M shares | ||
| Common stock, outstanding (in shares) | 28.6M shares | 29.7M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $104.8M | $150.2M | ||
| Investments, short-term | $203.5M | $295.4M | ||
| Accounts receivable, net of allowance for credit losses of $1,080 and $880, respectively | $119.7M | $93.1M | ||
| Inventories, net | $145.3M | $80.1M | ||
| Prepaid expenses and other current assets | $10.4M | $12.1M | ||
| Total current assets | $583.7M | $630.8M | ||
| Investments, long-term | $96.3M | $71.0M | ||
| Property and equipment, net | $97.9M | $71.9M | ||
| Operating lease right-of-use assets | $23.5M | $23.3M | ||
| Deferred tax assets | $88.7M | $13.0K | ||
| Other non-current assets | $17.3M | $11.3M | ||
| Total assets | $907.3M | $808.4M | ||
| Accounts payable | $36.6M | $38.7M | ||
| Accrued expenses | $59.5M | $49.8M | ||
| Total current liabilities | $96.1M | $88.5M | ||
| Operating lease liabilities, non-current portion | $30.0M | $30.0M | ||
| Other non-current liabilities | $104.0K | $148.0K | ||
| Total liabilities | $126.2M | $118.7M | ||
| Preferred Stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding | $0 | $0 | ||
| Common Stock, $0.001 par value, 200,000,000 shares authorized; 28,579,015 and 29,740,176 shares issued and outstanding at December 31, 2025 and 2024, respectively | $29.0K | $30.0K | ||
| Additional paid-in capital | $927.2M | $981.0M | ||
| Accumulated other comprehensive income | $464.0K | $536.0K | ||
| Accumulated deficit | -$146.5M | -$291.9M | ||
| Total stockholders' equity | $781.2M | $689.7M | $572.5M | $496.0M |
| Total liabilities and stockholders' equity | $907.3M | $808.4M | ||
| Allowance for credit loss | $1.1M | $880.0K | $1.6M | $36.0K |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred stock, issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, authorized (in shares) | 200.0M shares | 200.0M shares | ||
| Common stock, issued (in shares) | 28.6M shares | 29.7M shares | ||
| Common stock, outstanding (in shares) | 28.6M shares | 29.7M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income (loss) | $145.4M | $53.5M | -$21.2M |
| Depreciation and amortization | $14.0M | $6.5M | $2.8M |
| Accretion of investment discount | -$2.9M | -$8.9M | -$2.5M |
| Stock-based compensation expense | $130.3M | $116.0M | $82.5M |
| Deferred income taxes (benefit) | -$88.7M | $0 | $0 |
| Provision (benefit) for estimated credit losses | $200.0K | -$768.0K | $1.6M |
| Impairment of strategic investment | $4.0M | $0 | $0 |
| Other non-cash expenses | $2.1M | $1.5M | $2.1M |
| Accounts receivable | -$26.2M | -$2.6M | -$30.2M |
| Inventories | -$65.2M | -$46.2M | -$22.0M |
| Prepaid expenses and other current assets | $1.7M | -$2.3M | -$4.8M |
| Accounts payable | -$3.7M | $604.0K | $9.3M |
| Accrued expenses and other liabilities | $6.1M | $12.9M | $6.9M |
| Net cash provided by operating activities | $117.0M | $130.2M | $24.7M |
| Purchases of property and equipment | -$38.5M | -$39.1M | -$23.6M |
| Purchases of investments | -$240.3M | -$418.4M | -$281.2M |
| Proceeds from sales or maturities of investments | $310.4M | $344.6M | $10.2M |
| Purchases of strategic investments | -$10.1M | -$250.0K | -$250.0K |
| Net cash provided by (used in) investing activities | $21.4M | -$113.1M | -$294.8M |
| Proceeds from the exercise of stock options | $9.6M | $22.2M | $25.8M |
| Accelerated share repurchase of common stock | $0 | -$75.0M | $0 |
| Share repurchase of common stock | -$175.0M | $0 | $0 |
| Payment of taxes on net share settlement of equity awards | -$23.0M | -$5.2M | -$17.2M |
| Proceeds from the issuance of common stock from employee stock purchase plan | $5.0M | $5.6M | $5.3M |
| Net cash (used in) provided by financing activities | -$183.4M | -$52.4M | $13.9M |
| Effect of exchange rate on cash | -$310.0K | -$118.0K | $164.0K |
| Decrease in cash and cash equivalents | -$45.3M | -$35.4M | -$256.1M |
| Cash paid for interest | $137.0K | $22.0K | $0 |
| Property and equipment included in accounts payable and accrued expenses | $4.8M | $3.4M | $4.0M |
| Excise taxes accrued but not paid | $1.0M | $0 | $0 |
No quarter-by-quarter statement was filed.
Compare Inspire Medical Systems (United States) with another company
Leadership
Who has led Inspire Medical Systems (United States), and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
2010201520202025
- Chief executive officerTimothy P. Herbert May 2, 2018 to now14
- ChairTimothy P. Herbert Jun 4, 2024 to Jun 4, 202415
- PresidentTimothy P. Herbert May 2, 2018 to now14
- Chief financial officerMatthew J. Osberg Feb 24, 2026 to now16
- Chief financial officerRichard Buchholz May 2, 2018 to Feb 24, 202617
- Chief operating officerPhilip Ebeling Jun 9, 2020 to Feb 13, 202418
Board members and other officers (22)
- Chief People OfficerMelissa Mann Aug 1, 2024 to now19
- Chief Strategy OfficerCarlton Weatherby Aug 2, 2023 to now20
- Chief Medical OfficerCharisse Y. Sparks Aug 2, 2023 to May 31, 202421
- Chief Technology OfficerJohn Rondoni Jun 2, 2022 to now22
- OfficerBryan K. Phillips Jan 27, 2021 to now23
- Senior VP. & Sales & MarketingRandy Ban May 2, 2018 to now24
- Chief Comp Off & VP, Human ResSteven Jandrich May 2, 2018 to Jan 31, 202425
- Board memberMichael H. Carrel Jul 27, 2026 to now26
- Board memberCuret Myriam Dec 26, 2023 to now27
- Board memberCharisse Y. Sparks Aug 3, 2022 to Oct 17, 202328
- Board memberCynthia Burks Aug 4, 2022 to now29
- Board memberGeorgia Melenikiotou Jul 10, 2020 to now30
- Board memberShelley G. Broader Oct 22, 2020 to now31
- Board memberGary Lee Ellis Jul 29, 2019 to now32
- Board memberCasey M. Tansey May 2, 2018 to now33
- Board memberChau Quang Khuong May 2, 2018 to Oct 13, 202034
- Board memberJerry C. Griffin May 2, 2018 to Apr 3, 202435
- Board memberJoyce Erony May 2, 2018 to Jul 18, 201936
- Board memberMarilyn C. Nelson May 2, 2018 to May 1, 202437
- Board memberMudit K. Jain May 2, 2018 to Jul 14, 202038
- Board memberShawn McCormick May 2, 2018 to now39
- Board memberTimothy P. Herbert May 2, 2018 to now14
Timeline
Filings
513 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 59 major events, 322 insider forms, 36 large holders, 76 other. The latest 20:
- Sep 2, 20264 OWNERSHIP DOCUMENT EDGAR
- Aug 24, 2026144 EDGAR
- Aug 13, 2026SCHEDULE 13G/A EDGAR
- Aug 12, 2026SCHEDULE 13G EDGAR
- Aug 11, 20264 OWNERSHIP DOCUMENT EDGAR
- Aug 7, 2026144 EDGAR
- Aug 4, 20264 OWNERSHIP DOCUMENT EDGAR
- Aug 3, 202610-Q EDGAR
- Aug 3, 20268-K EDGAR
- Jul 31, 2026SCHEDULE 13G/A EDGAR
- Jul 28, 2026SCHEDULE 13G/A EDGAR
- Jul 27, 20264 OWNERSHIP DOCUMENT EDGAR
- Jul 27, 20263 OWNERSHIP DOCUMENT EDGAR
- Jul 24, 20268-K EDGAR
- Jul 22, 20268-K EDGAR
- Jul 17, 20264 OWNERSHIP DOCUMENT EDGAR
- Jul 17, 20264 OWNERSHIP DOCUMENT EDGAR
- Jul 17, 20264 OWNERSHIP DOCUMENT EDGAR
- Jul 17, 20264 OWNERSHIP DOCUMENT EDGAR
- Jul 2, 2026SCHEDULE 13G EDGAR
The 513 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
88 open-market trades by officers, directors and large owners since October 2021: 3 buys and 85 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 7, 2026 | Kelly Jason PSee Remarks | Sale | 963 | $59.55 | $57.3K | Form 4 |
| May 15, 2026 | Rondoni JohnSee Remarks | Sale | 2,641 | $43.28 | $114.3K | Form 4 |
| May 14, 2026 | Rondoni JohnSee Remarks | Sale | 700 | $43.01 | $30.1K | Form 4 |
| May 8, 2026 | mcCormick ShawnDirector | Sale | 696 | $45.31 | $31.5K | Form 4 |
| Jan 9, 2026 | Rondoni JohnSee Remarks | Sale | 109 | $100.00 | $10.9K | Form 4 |
| Dec 2, 2025 | mcCormick ShawnDirector | Sale | 1,200 | $139.00 | $166.8K | Form 4 |
| Nov 28, 2025 | mcCormick ShawnDirector | Sale | 2,000 | $127.48 | $255.0K | Form 4 |
| Aug 29, 2025 | Buchholz RichardInterim CFO | Sale | 11,000 | $93.39 | $1.0M | Form 4 |
| Aug 8, 2025 | Curet MyriamDirector | Sale | 4 | $77.28 | $309 | Form 4 |
| May 19, 2025 | Rondoni JohnSee Remarks | Sale | 1,734 | $149.38 | $259.0K | Form 4 |
| May 8, 2025 | Curet MyriamDirector | Sale | 2 | $153.22 | $306 | Form 4 |
| May 2, 2025 | mcCormick ShawnDirector | Sale | 360 | $160.00 | $57.6K | Form 4 |
| Apr 7, 2025 | Curet MyriamDirector | Buy | 1 | $148.26 | $148 | Form 4 |
| Mar 20, 2025 | Curet MyriamDirector | Buy | 4 | $163.84 | $655 | Form 4 |
| Mar 3, 2025 | Ban RandySee Remarks | Sale | 3,947 | $185.84 | $733.5K | Form 4 |
| Mar 3, 2025 | Rondoni JohnSee Remarks | Sale | 2,287 | $185.60 | $424.5K | Form 4 |
| Feb 13, 2025 | Ban RandySee Remarks | Sale | 25,584 | $183.50 | $4.7M | Form 4 |
| Feb 11, 2025 | Rondoni JohnSee Remarks | Sale | 583 | $170.49 | $99.4K | Form 4 |
| Jan 7, 2025 | Rondoni JohnSee Remarks | Sale | 58 | $215.00 | $12.5K | Form 4 |
| Nov 1, 2024 | Rondoni JohnSee Remarks | Sale | 8,703 | $193.47 | $1.7M | Form 4 |
All 88 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Soleus Capital Master Fund, L.P.SCHEDULE 13G/A, 2 filings May 27, 2026 to Aug 13, 202640
- AQR CAPITAL MANAGEMENT LLCSCHEDULE 13G, 1 filing Aug 12, 202641
- VANGUARD PORTFOLIO MANAGEMENT LLCSCHEDULE 13G/A, 2 filings Apr 29, 2026 to Jul 31, 202642
- BlackRockSCHEDULE 13G/A, 3 filings Oct 7, 2024 to Jul 28, 202643
- D. E. SHAW & CO, L.P.SCHEDULE 13G, 1 filing Jul 2, 202644
- Wellington Management CompanySCHEDULE 13G/A, 2 filings Feb 10, 2026 to May 15, 202645
- James E. FlynnSCHEDULE 13G/A, 2 filings Nov 13, 2025 to May 14, 202646
- VANGUARD CAPITAL MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 30, 202647
- VANGUARD GROUP INCSCHEDULE 13G/A, 6 filings Feb 10, 2022 to Mar 27, 202648
- CITADEL ADVISORS LLCSCHEDULE 13G/A, 2 filings Oct 6, 2025 to Feb 17, 202649
- Dragoneer Investment Group, LLCSCHEDULE 13G/A, 2 filings Aug 14, 2025 to Nov 14, 202550
- WASATCH ADVISORS LPSCHEDULE 13G/A, 2 filings May 13, 2025 to Nov 12, 202551
- FMR LLCSCHEDULE 13G/A, 7 filings Jan 10, 2022 to Oct 7, 202552
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 4,737,519 | $211.3M | 0.0% | +1,187,965 |
| Wellington Management Group Llp | 2,382,660 | $106.3M | 0.0% | −153,294 |
| Vanguard Portfolio Management LLC | 2,088,961 | $93.2M | 0.0% | +451,788 |
| Soleus Capital Management, L.P. | 1,931,436 | $86.2M | 3.0% | +1,355,137 |
| Aqr Capital Management LLC | 1,856,800 | $80.9M | 0.0% | +1,548,138 |
| Assenagon Asset Management S.A. | 1,728,790 | $77.1M | 0.1% | +1,208,616 |
| UBS Group AG | 1,645,511 | $73.4M | 0.0% | +1,006,583 |
| D. E. Shaw & Co., Inc. | 1,470,462 | $65.6M | 0.0% | +281,925 |
| Nomura Holdings Inc | 1,369,410 | $61.1M | 0.3% | New |
| Deerfield Management Company, L.P. | 1,296,862 | $57.9M | 0.7% | −1,406,376 |
| Vanguard Capital Management LLC | 1,270,928 | $56.7M | 0.0% | +4,190 |
| State Street Corp | 1,206,494 | $53.8M | 0.0% | +250,483 |
| Morgan Stanley | 791,222 | $35.3M | 0.0% | −659,412 |
| Artisan Partners Limited Partnership | 732,323 | $32.7M | 0.1% | −48,252 |
| Geode Capital Management, LLC | 700,836 | $31.3M | 0.0% | +190,602 |
| Braidwell LP | 677,570 | $30.2M | 1.2% | No change |
| Goldman Sachs Group Inc | 645,858 | $28.8M | 0.0% | −18,145 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 546,020 | $24.4M | 0.0% | +97,233 |
| Nantahala Capital Management, LLC | 538,948 | $24.0M | 0.7% | New |
| Citadel Advisors LLC | 506,334 | $22.6M | 0.0% | +112,258 |
| Bnp Paribas Financial Markets | 428,069 | $19.1M | 0.0% | +108,311 |
| Renaissance Technologies LLC | 426,000 | $19.0M | 0.0% | −43,968 |
| ADAR1 Capital Management, LLC | 374,617 | $16.7M | 0.8% | −30,580 |
| Aberdeen Group plc | 358,968 | $16.0M | 0.0% | −118,508 |
| Northern Trust Corp | 334,039 | $14.9M | 0.0% | +137,006 |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Apr 10, 2023 | Daniel S. GoldmanDemocratic, House | Partial sale | $1,001 - $15,000 | +158.2% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
Links
- Websitewww.inspiresleep.com1
- WikidataQ50038595
- SEC EDGARCIK 1609550
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15SEC EDGARTimothy P. Herbert, Chair
- 16
- 17
- 18
- 19SEC EDGARMelissa Mann, Chief People Officer
- 20
- 21
- 22
- 23SEC EDGARBryan K. Phillips, Officer
- 24
- 25
- 26SEC EDGARMichael H. Carrel, Board member
- 27SEC EDGARCuret Myriam, Board member
- 28SEC EDGARCharisse Y. Sparks, Board member
- 29SEC EDGARCynthia Burks, Board member
- 30SEC EDGARGeorgia Melenikiotou, Board member
- 31SEC EDGARShelley G. Broader, Board member
- 32SEC EDGARGary Lee Ellis, Board member
- 33SEC EDGARCasey M. Tansey, Board member
- 34SEC EDGARChau Quang Khuong, Board member
- 35SEC EDGARJerry C. Griffin, Board member
- 36SEC EDGARJoyce Erony, Board member
- 37SEC EDGARMarilyn C. Nelson, Board member
- 38SEC EDGARMudit K. Jain, Board member
- 39SEC EDGARShawn McCormick, Board member
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52